Oxford’s COVID-19 Vaccine in brief

27 March 2020

Vaccine development is one of Oxford’s biggest strengths and Oxford is currently developing a single-dose vaccine candidate at the University’s Jenner Institute. We are using a non-replicating viral vector platform and believe it may be the world’s most promising and advanced candidate. Oxford also has a strong track record in developing leading vaccines for Ebola and MERS, and has about 400 people (c.60 PIs) working in this area at present. Oxford has already started early trials and will be ready for full human trials in May or June if we can secure funding over the coming weeks. Oxford also needs funds to manufacture the vaccines alongside this to save time. The hope is that if we are successful and can get hold of the required funding, we’ll be aiming to be roll out at the end of this year.